Haleon reports 2025 results with 3% organic growth and margin expansion

Haleon plc

Haleon plc (LON:HLN, NYSE: HLN) has announced its preliminary full year results statement for the year ended 31 December 2025.

The preliminary full year results statement will also be available on the Haleon website www.haleon.com/investors, and the results have been submitted in full unedited text to the Financial Conduct Authority’s National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

Dividend

Reflecting the strength of FCF generation during the year, alongside strong organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share which represents a payout ratio of approximately 38% of 2025 adjusted earnings (2024: 37%). This includes a final dividend of 4.9p per ordinary share.

Subject to shareholder approval, the final dividend will be paid on 14 May 2026 to holders of ordinary shares and US American Depositary Shares (ADS) on the register as of 10 April 2026 (the record date). The ex-dividend date for ordinary shares will be 9 April 2026 and for US American Depositary Shares (ADS) 10 April 2026. For ordinary shareholders wishing to participate in the Dividend Reinvestment Programme (DRIP), the election deadline will be 24 April 2026. The DRIP is provided by Equiniti Financial Services Limited, more information is available at www.shareview.co.uk/info/drip.

Subject to market conditions and Board approval, Haleon expects to grow its ordinary dividend at least in line with adjusted earnings.

Presentation for analysts and shareholders

A recorded results presentation by Brian McNamara, Chief Executive Officer, and Dawn Allen, Chief Financial Officer, will be available shortly after 7:00am GMT (8:00 am CET) on 25 February 2026 and can be accessed at www.haleon.com/investors. This will be followed by a Q&A session at 8:45am GMT (9:45am CET).

For analysts and shareholders wishing to ask questions, please use the dial-in details below which will have a Q&A facility:

UK:+44 (0) 808 189 0158
US:+1 855 979 6654
All other:+44 (0) 203 936 2999
Passcode:049869

An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.

Share on:

Latest Company News

Haleon reports 2025 results with 3% organic growth and margin expansion

Haleon delivered 3% organic revenue growth in 2025, supported by strong performance in Oral Health and emerging markets. Adjusted operating profit rose 10.5% organically, with margin expansion driven by productivity gains and disciplined investment.

Haleon appoints Vindi Banga as new Chair as Sir Dave Lewis steps down

Haleon has confirmed that Sir Dave Lewis will step down as Chair at the end of December 2025, with Vindi Banga appointed to take over from January 2026.

Haleon delivers 3.4% organic revenue growth in Q3 2025 driven by oral health and VMS

Haleon reported Q3 2025 revenue of £2.8 billion, reflecting 3.4% organic growth, led by strong performances in Oral Health and Vitamins, Minerals and Supplements.

Haleon Plc Q1 2025: £2.85bn revenue, 3.5% organic growth

Haleon plc has released its Q1 trading statement for 2025, with a presentation and Q&A session led by CFO Dawn Allen scheduled for April 30.

Haleon Plc publishes 2024 Annual Report

Haleon plc has released its Annual Report for 2024, detailing vital financial information and upcoming AGM plans. Discover key insights for investors now.

Haleon Plc reports strong Q3 organic revenue growth, guidance reaffirmed

Haleon plc releases its Q3 2024 trading update, now available for review. Join the presentation on October 31 for in-depth analysis and insights.

    Search

    Search